IRVINE, Calif. -- IDM Pharma, Inc. (NASDAQ:IDMI), a company focused on the development of innovative cancer products, including MEPACT(R) (mifamurtide), which was recently approved in Europe for the treatment of osteosarcoma, today announced receipt of a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") informing the Company that it does not comply with the requirement to maintain a minimum of $10 million in stockholders' equity for continued listing on the Nasdaq Global Market.
IDM has until April 23, 2009 to provide Nasdaq a specific plan to achieve and sustain compliance with all Nasdaq Global Market listing requirements. If Nasdaq accepts the Company's plan, the Company may be granted a period of up to 105 days within which it can regain compliance with such listing requirements. The Company is currently evaluating options including submission of a compliance plan with Nasdaq, application to transfer to the Nasdaq Capital Market, or a parallel approach. There can be no assurance that such compliance plan will be sufficient to avoid delisting or that such application to transfer to the Nasdaq Capital Market will be approved.
As previously disclosed, IDM has engaged JMP Securities, LLC, an investment bank, to advise the Company in exploring available strategic alternatives, including possible merger or acquisition opportunities.
About IDM Pharma
IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.
For more information about the company and its products, visit www.idm-pharma.com.
ABOUT PENNYSTOCKCHASER.COM
PennyStockChaser.com's alerts are daily e-mails on stocks that are hot in the market. These include stocks with huge volume, penny stocks, new 52 week highs or lows, stocks with technical indicators, and much more. Our stock alerts have done very well in the last couple of weeks.
We encourage investors to subscribe to our FREE e-mail alerts by visiting: http://pennystockchaser.com/join-now/ JOIN TODAY. READ OUR PICKS. GET READY TO PROFIT.
PennyStockChaser.com is a leading stock website that provides free daily alerts on stocks that are moving up. PennyStockChaser.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research reports, analysis, and newsletters. To feature a company on our web site please contacts us at editorial@pennystockchaser.com. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PennyStockChaser, Editorial Staff e-mail: editorial@pennystockchaser.com WWW: http://pennystockchaser.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index